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jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ jcc as eDeep vein thrombosis (DVT) can cause both pulmonary
thromboembolism (PTE) and post-thrombotic syndrome (PTS).
DVT treatment aims to relieve the acute symptoms of limb swelling
and pain, reduce the risk of PTE, and prevent long-term disability
from chronic venous insufﬁciency including persistent leg pain and
swelling, pigmentation, venous claudication, and skin ulceration.
Standard anticoagulation can decrease PTE and thrombus propaga-
tion but cannot gain early reduction of thrombus burden.
Approximately half of the patients with iliofemoral DVT treated
by anticoagulation alone develop PTS [1,2]. Early thrombus removal
appears to be important to gain rapid symptom relief, preserve
valvular function, and prevent PTS [3–5]. Systemic thrombolysis is
more effective than heparinization [6], but was discouraged by high
rates of incomplete clot lysis and bleeding complications [7].
Catheter-directed thrombolysis (CDT) offers signiﬁcant advan-
tages over systemic thrombolysis, which can fail to reach and
penetrate an occluded venous thrombus [8–10]. With CDT, clot
lysis rate can be improved, and treatment duration and bleeding
complication rate can be reduced by delivery of higher concentra-
tions of drug to thrombus.
In this issue of the Journal, Okabe et al. reported that a 24-year-
old woman with acute iliofemoral DVT and submassive PTE was
successfully treated with CDT using monteplase after catheter
aspiration and fragmentation for DVT in conjunction with
retrievable inferior vena cava (IVC) ﬁlter which was removed
after clot lysis [11]. The efﬁcacy of endovascular treatment for
acute iliofemoral DVT was also demonstrated in this case.
The CaVenT (Catheter-directed Venous Thrombolysis in Acute
Iliofemoral Vein Thrombosis) study provided good quality
evidence that venous patency rate and venous valvular function
were better preserved in patients with acute iliofemoral DVT
treated with CDT than anticoagulation alone [12]. This study was
an open-label, randomized controlled trial which enrolled
209 patients with ﬁrst-time iliofemoral DVT within 21 days from
symptom onset. It demonstrated that iliofemoral patency after
6 months was signiﬁcantly higher on CDT than anticoagulationDOI of original article: http://dx.doi.org/10.1016/j.jccase.2014.05.011
http://dx.doi.org/10.1016/j.jccase.2015.01.003
1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsalone (65.9% vs 47.4%, p = 0.012) and PTS assessed by Villalta score
at 24 months was signiﬁcantly lower on CDT than anticoagulation
alone (41.1% vs 55.6%, p = 0.047).
The ATTRACT (Acute Venous Thrombosis: Thrombus Removal
with Adjunctive Catheter-Directed Thrombolysis) study is an
ongoing US National Institutes of Health-sponsored, phase III,
multicenter, randomized, open-label, assessor-blinded, parallel
two-arm, controlled clinical trial [13]. Approximately 692 patients
with acute proximal DVT involving the femoral, common femoral,
and/or iliac vein are being randomized to receive pharmacome-
chanical catheter-directed thrombolysis (PCDT) [using the Trellis
Peripheral Infusion System (Covidien, Inc., Mansﬁeld, MA, USA) or
the AngioJet Rheolytic Thrombectomy System (MEDRAD Inter-
ventional – Bayer, Minneapolis, MN, USA)] + standard therapy
versus standard therapy alone. The primary study hypothesis is
that PCDT will reduce the proportion of patients who develop PTS
within 2 years. Secondary outcomes include safety, general and
venous disease-speciﬁc quality of life, relief of early pain and
swelling, and cost-effectiveness. This study will provide further
evidence regarding the clinical utility of these techniques.
Supplementary stent implantation for persistent signiﬁcant
stenosis or obstruction in iliac vein following CDT or PCDT,
especially left side so-called iliac compression syndrome, should
be performed to gain outﬂow tract venous ﬂow. Balloon venoplasty
alone is often ineffective due to recoil. Venous stenting appears to
improve the iliofemoral patency and clinical outcome [14].
The careful selection of patients is important to the success of
these techniques, e.g. duration of symptoms, anatomic distribution
and form of thrombus, and the risk of complications (Fig. 1). A
scientiﬁc statement from the American Heart Association recom-
mended the following: CDT or PCDT is reasonable as ﬁrst-line
treatment of patients with acute iliofemoral DVT to prevent PTS in
selected patients at low risk of bleeding complications (Class IIa;
Level of Evidence B). CDT or PCDT should not be given to most
patients with chronic DVT symptoms (>21 days) or patients who
are at high risk for bleeding complications (Class III; Level of
Evidence B). Systemic ﬁbrinolysis should not be given routinely to
patients with iliofemoral DVT (Class III; Level of Evidence A) [15]. reserved.
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Fig. 1.
Treatment strategy for acute iliofemoral DVT.
*Necessity of non-permanent IVC ﬁlter is controversial.
CDT, catheter-directed thrombolysis; CT, computed tomography; PCDT, pharmacomechanical catheter-directed thrombolysis; PTE, pulmonary
thromboembolism; RV, right ventricle; DVT, deep vein thrombosis; IVC, inferior vena cava; VTE, venous thromboembolism.
Editorial / Journal of Cardiology Cases 11 (2015) 127–128128There are a lot of unresolved issues such as the optimal dose of
thrombolytic agents, appropriate duration from the onset for this
treatment, necessity of non-permanent IVC ﬁlter for PTE protection
during this procedure, and cost effectiveness of this treatment.
Further evidence regarding this treatment should be evaluated in
the future.
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